MD Farma Closes Series A Funding and Changes Name to Corganics as the Company Expands Clinical Cannabinoid (CBD) Product Lines Sold Only in Healthcare Facilities
Summary
DALLAS, Nov. 30, 2021 /PRNewswire/ -- MD Farma, healthcare professionals most trusted and recommended clinical cannabinoid (CBD) company, announced today a Series A investment from Altacrest Capital. "This investment is an exciting step forward in fulfilling our mission to deliver effective clinical cannabinoid products that healthcare professionals and their patients can trust," said Chad Collins, co-founder of Corganics. With this funding round the company will accelerate its ability to reach more healthcare professionals by amplifying education on cannabinoid therapy, expanding operations, increasing its commercial footprint and investing in research and development innovations. With these strategic developments, Corganics mission remains steadfast: helping healthcare professionals become a relevant patient partner by providing safe, effective all-natural, organic products and clinical education. "We are excited about the potential of hemp-based, clinical cannabinoid therapies and strongly believe in the strategy of involving healthcare professionals to help differentiate quality from that of the retail sector," said Brien Davis, partner at Altacrest Capital.